A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

332

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastro-enteropancreatic Neuroendocrine Tumor

Interventions

DRUG: CAM2029
DRUG: Octreotide LAR
DRUG: Lanreotide ATG

Sponsor

Camurus AB